Tango Therapeutics has dosed the first subject in the Phase I/II trial assessing TNG462 in combination with Revolution Medicines’ daraxonrasib or zoldonrasib for methylthioadenosine phosphorylase (MTAP)-deleted and RAS mutant metastatic pancreatic or lung cancer.
The trial aims to evaluate the pharmacokinetics, safety, antitumor activity, and pharmacodynamics of these combinations.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will focus on individuals with MTAP loss and RAS mutant metastatic pancreatic adenocarcinoma or locally advanced or metastatic non-small cell lung cancer.
It will be carried out in two parts: a dose escalation phase (Phase I) and a dose expansion phase (Phase II).
The individual arms of Phase II will begin once the maximum tolerated dose and/or recommended doses have been established.
Currently, two US locations are participating in this study.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTango Therapeutics’ research and development president Adam Crystal said: “Almost all MTAP-del pancreatic and approximately 30% of lung cancers have a co-occurring RAS mutation, and preclinical data show strong combination activity of TNG462 with either daraxonrasib or zoldonrasib.
“Single agent clinical data to date have demonstrated these molecules to be well-tolerated and active in pancreatic cancer and lung cancer, supporting the potential for these combinations to become transformative therapies.
“The potential of these combinations further strengthens our conviction that TNG462 may play a major role in changing the treatment paradigm for patients with MTAP-deleted cancers.”
The MTA-cooperative protein arginine methyltransferase 5 inhibitor, TNG462, is being assessed as a single agent in the Phase I/II trial, with data anticipated in the latter half of this year.
This monotherapy data is expected to give critical information that could lead to a registrational trial in pancreatic cancer next year and further the development plan for lung cancer.
Tango Therapeutics is focused on advancing precision medicine for cancer treatment.
Last month, the company announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial in individuals with MTAP-deleted solid tumours, mainly focusing on glioblastoma (GBM).
